Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

NIH 2OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Gynecologic 1

Conditions

Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma, Alveolar 1Rhabdomyosarcoma 1Endometrial Adenocarcinoma 1

Interventions

Specimen Handling 200Magnetic Resonance Spectroscopy 151Biopsy 113Nivolumab 40Immunoglobulin G 40Disulfides 40Cisplatin 38Cyclophosphamide 37Platinum 36Paclitaxel 361,2-diaminocyclohexaneplatinum II citrate 36Carboplatin 35Taxes 34Radiation 34X-Rays 29Radiotherapy 28pembrolizumab 27Doxorubicin 25Bevacizumab 24olaparib 22atezolizumab 22Gemcitabine 22Vincristine 19Prednisone 19fludarabine 18Ipilimumab 18CTLA-4 Antigen 18venetoclax 17durvalumab 17Phantoms, Imaging 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × temsirolimus × 30 days × Clear all
NCT00977574 2026-05-29

Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
349 enrolled 11 charts
GynecologicSarcoma

Endometrial Adenocarcinoma

NCT02567435 2026-05-27

Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma

National Cancer Institute (NCI)

Phase 3 Active not recruiting
325 enrolled 14 charts
Sarcoma

Rhabdomyosarcoma, Rhabdomyosarcoma, Alveolar, Rhabdomyosarcoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡